SK pharmteco, a global contract development and manufacturing organization (CDMO), has opened its new Current Good Manufacturing Practice (CGMP) plasmid suite at its facility in King of Prussia, Pennsylvania. This strategic expansion underscores SK pharmteco’s commitment to providing a reliable and scalable supply of high-quality plasmids, a critical component in developing life-changing cell and gene therapies (CGTs).

Located strategically in the heart of a central hub for potential customers and biopharmaceutical innovation, this new CGMP suite enhances SK pharmteco’s position as a key partner in advancing the CGT landscape.

“This new CGMP plasmid suite in King of Prussia represents a solid investment in our capabilities and our commitment to the cell and gene therapy sector,” said Joerg Ahlgrimm, CEO at SK pharmteco. “We understand the vital role that high-quality plasmids play in developing these transformative medicines, and this expansion will enable us to serve our clients better and ultimately contribute to bringing these therapies to patients in need.”

SK pharmteco’s 300,000 sq. ft. King of Prussia facility offers a wide range of services, including process development and plasmid manufacturing with four dedicated suites capable of producing three distinct plasmid grades.

Additionally, the site features two independent aseptic fill & finish operations and provides integrated CDMO and contract analytical testing services, as well as an in-house CGMP cell line, further streamlining the development and manufacturing process for cell and gene therapies.

SK pharmteco’s investment in this new CGMP plasmid suite demonstrates the company’s proactive approach to supporting the growth and accessibility of CGTs.